Global surveillance of trends in cancer survival: analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers during 2000–2014 from 322 population-based registries in 71…
By C. Allemani, T. Matsuda, V. D. Carlo, R. Harewood, M. Matz, M. Nikšić, A. Bonaventure, M. Valkov, Christopher J. Johnson, Jacques Estève and 584 more. The Lancet, 2018
4,152 citations recorded by the source corpus.
Background In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival, as a metric of the effectiveness of health systems and to inform global policy on cancer control. Methods CONCORD-3 updates the world-wide surveillance of cancer survival to 2014, with individual data for 37.5 million patients diagnosed with cancer during the 15-year period 2000–2014. Data were provided by 322 population-based cancer registries in 71 countries and territories, of which 47 provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate and melanoma of the skin in adults, and brain tumours, leukaemias and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated five-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings For most cancers, five-year net survival remains among the highest in the world in the US and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas and lung. For women diagnosed during 2010–2014, the predicted five-year survival for breast cancer is now close to 90% in the US and in Australia, but international differences remain very wide, with levels as low as 40% in South Africa. For gastrointestinal cancers, the highest levels of five-year survival are seen in South-East Asia, in Korea for cancers of the stomach (69%), colon (72%) and rectum (71%), in Japan for oesophageal cancer (36%) and in Taiwan for liver cancer (28%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (60% in Korea, 52% in Taiwan, 50% in China), and for both lymphoid malignancies (53% in Korea, 51% in Taiwan, 38% in China) and myeloid malignancies (46% in Korea, 33% in Taiwan, 25% in China). For children diagnosed during 2010–2014, five-year survival for acute lymphoblastic leukaemia ranged from 66% in Thailand to 95% in Finland. Five-year survival from brain tumours in children is higher than for adults, and the global range is very wide (from 45% in Thailand to 80% in Sweden and Denmark). Interpretation The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed world-wide every year. It contributes to the evidence base for global policy on cancer control. From 2017, the Organisation for Economic Co-operation and Development will use findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries world-wide. It is crucial for governments to recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer.
Subfields: Epidemiology, Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/8d2df9e7f08a76b779ad38d101af0a0f5526e981
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Oncology
Citations in the corpus
- Delivering Quality Health Services: A Global Imperative for Universal Health Coverage (2018, background): “Much progress has been made in improving some aspects of quality of health care across the world, for example with regard to cancer survival rates and mortality from cardiovascular diseases (1, 2).”
- Current and future burden of breast cancer: Global statistics for 2020 and 2040 (2022, background): “While 5-year survival rates for breast cancer exceed 90% in most high-income countries, this figure was 66% for 12 sub-Saharan African countries combined for cases diagnosed 2008–2015 [30], with country-specific estimates as low as 12% in Uganda [31].”
- Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020 (2021, background): “5%) [34], leading to the poor prognosis and low survival of breast cancer in China [62].”
- Global patterns and trends in breast cancer incidence and mortality across 185 countries (2025, neutral): “9).”
- Global colorectal cancer burden in 2020 and projections to 2040 (2021, background): “Diagnosis at the different clinical stages of CRC may partially explain the marked differences in survival rates [15].”
- Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 (2021, background): “In contrast, the most common cancers in US and UK were cancers with a low mortality rate, such as prostate cancer, tumors arising from corpus uteri, and skin melanoma [23].”
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021, background): “For women diagnosed with EBC, the 5-year survival probability is w 96% in Europe.”